News Sentiment

ALLO sentiment intelligence

Allogene Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.00 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.8% over one week, +5.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend inactive 5.3% over four weeks
Fair value -16.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 43
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
TradingView 7
GlobeNewswire 3
simplywall.st 3
Quartr 2
The Business Journals 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 17
Analyst action 3
Regulatory and legal 2
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
The Manila Times Direct company coverage

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics announced the publication of complete Phase 1 data for its investigational therapy ALLO-316 in the Journal of Clinical Oncology, showing durable remissions in metastatic solid tumors. The TRAVERSE study, conducted in collaboration with The University of Texa

Tone
Positive 73/100
Event
Regulatory and legal
Published
15 Jul 2026 12:38
Source
The Manila Times
Quartr Direct company coverage

Allogene Therapeutics (ALLO) Q3 2024 earnings summary

Allogene Therapeutics released its Q3 2024 earnings summary, highlighting the advancement of its key trials, including the pivotal Phase 2 ALPHA3 trial for cema-cel, with enrollment expected to complete in H1 2026. The company reported $403.4 million in cash, cash equivalents, an

Tone
Positive 66/100
Event
Earnings
Published
14 Jul 2026 00:11
Source
Quartr
Quartr Direct company coverage

Allogene Therapeutics (ALLO) Proxy filing Summary

Allogene Therapeutics (ALLO) issued a proxy filing summary on May 21, 2026, correcting total compensation figures for Dr. Chang (2024), Dr. Roberts (2025), and Mr. Parker (2025) in their Summary Compensation Table, with no other changes to the proxy statement or proposals for the

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 09:40
Source
Quartr
The Business Journals Direct company coverage

Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution

Zach Roberts, the new CEO of Allogene Therapeutics Inc., is advocating for a revolutionary approach to cancer cell therapy. He aims to champion new methods to address this deadly disease. The article describes Roberts' vision for the future of cancer treatment at Allogene.

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 13:54
Source
The Business Journals
Stock Titan Direct company coverage

Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs

Allogene Therapeutics President and CEO Zachary Roberts was granted 476,190 stock options with an exercise price of $2.11 per share and 134,530 Restricted Stock Units (RSUs). These equity awards are compensation-related and not open-market transactions. The stock options vest ove

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:51
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO

The article focuses on the enterprise value to EBITDA forward for Allogene Therapeutics, Inc. (NASDAQ:ALLO). It appears to be a stub or a data point from a financial platform like TradingView, indicating that specific financial metrics are available for the company.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO

This page provides financial information for Allogene Therapeutics, Inc. (NASDAQ: ALLO), focusing on its Price to Earnings Forward metric. The content highlights the company's stock market data and emphasizes that specific financial values for this metric are presented within the

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 23:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO

This article provides financial information for Allogene Therapeutics, Inc. (ALLO), specifically focusing on its enterprise value to revenue forward. The data is presented within the context of the Blue Ocean Alternative Trade System (BOATS) on the TradingView platform.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Allogene Therapeutics, Inc. – BOATS:ALLO

This article provides the "Price to sales forward" metric for Allogene Therapeutics, Inc. (ALLO), listed on the Blue Ocean Alternative Trade System (BOATS). It notes the market is currently closed with no trades. The content is primarily a data point surrounded by navigation and

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:10
Source
TradingView
Stock Titan Direct company coverage

Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery

Allogene Therapeutics director Owen N. Witte was granted 95,400 Restricted Stock Units (RSUs), which vest in two equal semi-annual installments over one year. Witte has elected to defer the receipt of the underlying common stock until 30 days after his continuous service terminat

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:12
Source
Stock Titan
TradingView Direct company coverage

Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO)

This article provides an overview of Allogene Therapeutics, Inc. (NASDAQ: ALLO) financials, stock performance, and analyst forecasts. It includes key figures such as the current stock price, market capitalization, earnings per share, and revenue, alongside analysts' high and low

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

ALLO Forecast — Price Target — Prediction for 2027

This article provides an overview of Allogene Therapeutics, Inc. (ALLO) stock analysis, including its current price, analyst price targets, and future predictions. It details the company's financial performance, market capitalization, earnings reports, and employee count, alongsi

Tone
Positive 63/100
Event
Analyst action
Published
25 Jun 2026 19:09
Source
TradingView
Pharma Voice Direct company coverage

Recent pharma exec shake-ups signal strategic shifts

Recent executive movements at major pharmaceutical companies like Novo Nordisk, Genentech, and Allogene reflect strategic adjustments within the industry. Novo Nordisk saw a significant M&A executive depart, while Genentech underwent leadership layoffs due to pipeline restructuri

Tone
Positive 63/100
Event
Market update
Published
24 Jun 2026 13:10
Source
Pharma Voice
Stock Titan Direct company coverage

Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs

Allogene Therapeutics director Deborah M. Messemer was granted 95,400 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs, which carry no purchase price, give her the contingent right to receive 95,400 shares of Allogene common stock upon vesting. The ves

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 07:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Allogene Therapeutics Inc. as of June 23. It includes the company's stock symbol ALLO and its current price performance, noting a -1.43% change. The content primarily states the filing without providing further detail

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 21:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award

Allogene Therapeutics director Vicki L. Sato was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two equal semi-annual installments over one year, contingent on her continued service. The filing, a Form 4, indicates this is an equ

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Allogene Therapeutics (ALLO) director receives 144,400 stock options grant

Allogene Therapeutics director Stephen Mayo was granted 144,400 stock options with an exercise price of $2.00 per share. These options vest in 12 equal monthly installments and expire on June 18, 2036. Following this grant, Mayo holds options for 144,400 shares of Allogene common

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery

Allogene Therapeutics, Inc. (ALLO) director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units (RSUs) as part of her compensation. These RSUs will vest in two semi-annual installments over one year, contingent on her continued service. Barrett has opted to defer the d

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan

Allogene Therapeutics (NASDAQ: ALLO) announced that its stockholders approved an increase in authorized common shares from 400 million to 800 million at the 2026 Annual Meeting. This change, effective June 18, 2026, provides the company with greater flexibility for future equity

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 19:40
Source
Stock Titan
TradingView Direct company coverage

ALLO: All proposals, including director elections and share increase, were approved without contest

Allogene Therapeutics, Inc. (ALLO) held its 2026 AGM where all five key proposals were approved unanimously. These proposals included director elections, executive compensation, annual advisory votes, an increase in authorized shares, and auditor ratification. No questions were r

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 15:40
Source
TradingView
TradingKey Direct company coverage

Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Allogene Therapeutics Inc (ALLO), including business segments, regional revenue, and profit contribution. However, the core information indicates that the relevant financial data has not yet been disclosed b

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 18:39
Source
TradingKey
Insider Monkey Direct company coverage

10 Small Cap Stocks with Potential to Rise 1000 Percent

This article highlights small-cap stocks with significant growth potential, focusing on Allogene Therapeutics, Inc. (NASDAQ:ALLO) as a key example. Allogene is a clinical-stage biotechnology company developing CAR T cell therapies for cancer and autoimmune diseases, with importan

Tone
Positive 73/100
Event
Market update
Published
16 Jun 2026 14:09
Source
Insider Monkey